The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...
After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.
Complaints of poor medical care prompted Orange County’s emergency agency to revoke hospital’s title as a stroke receiving ...
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...
The company said Tuesday that the FDA lifted the hold on an Investigational New Drug Application for a phase 3 clinical trial of nexiguran ziclumeran, or nex-z, for patients with a genetic disease ...
The FDA has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 phase 3 trial of nexiguran ziclumeran, or nex-z: a CRISPR-based gene therapy for patients with hereditary transthyretin ...
An elderly woman endured severe pain at a government hospital in Maharashtra’s Beed district after a broken lift and a locked ...
SIOUX FALLS, SD - January 23, 2026 - PRESSADVANTAGE - Vance Thompson Vision is drawing attention to its advanced ...
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in ...
Investing.com -- Intellia Therapeutics (NASDAQ:NTLA) stock soared 20% Tuesday after the U.S. Food and Drug Administration (FDA) lifted a clinical hold on the company’s MAGNITUDE-2 Phase 3 trial for ...
"He’s really cool and chill," Wilsey said. "We talked about sports and the draft because it was right before the draft." ...
A Maryland State Police helicopter was called in for a dramatic cross-state rescue in Pennsylvania after a 23-year-old hiker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results